scholarly journals A pragmatic study evaluating NEPA versus aprepitant for prevention of CINV in patients receiving moderately emetogenic chemotherapy

2021 ◽  
Author(s):  
Laurent Zelek ◽  
Philippe Debourdeau ◽  
Hugues Bourgeois ◽  
Jean Philippe Wagner ◽  
Fabien Brocard ◽  
...  
Keyword(s):  
Emetogenic Chemotherapy ◽  
Moderately Emetogenic Chemotherapy ◽  
Pragmatic Study

The impact of postchemotherapy nausea and vomiting on quality of life after moderately emetogenic chemotherapy

1998 ◽  
Vol 6 (4) ◽  
pp. 389-395 ◽  
Author(s):  
J. J. Rusthoven ◽  
David Osoba ◽  
Charles A. Butts ◽  
Louise Yelle ◽  
Helen Findlay ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Emetogenic Chemotherapy ◽  
Nausea And Vomiting ◽  
Moderately Emetogenic Chemotherapy ◽  
The Impact

scholarly journals Management of chemotherapy induced emesis

2004 ◽  
Vol 12 (3) ◽  
pp. 173-176
Author(s):  
Fausto Roila
Keyword(s):  
Rescue Therapy ◽  
Emetogenic Chemotherapy ◽  
Delayed Emesis ◽  
Moderately Emetogenic Chemotherapy ◽  
Antiemetic Drug ◽  
Acute Emesis ◽  
Antiemetic Prophylaxis ◽  
Minimal Emetogenic Chemotherapy ◽  
Low Emetogenic Chemotherapy ◽  
Important Progress

Important progress has been achieved in the last few years in the prevention of chemotherapy-induced nausea and vomiting thanks to the introduction in clinical practice first of the 5-HT3 antagonists and of the NK1 antagonists more recently. To prevent acute emesis induced by cisplatin, moderately emetogenic chemotherapy, a combination of aprepitant plus a 5-HT3 antagonist and dexamethasone is now the most efficacious regimen. For the prevention of delayed emesis induced by cisplatin, moderately emetogenic chemotherapy, a combination of dexamethasone plus aprepitant or metoclopramide or a 5- HT3 antagonist / dexamethasone or a 5-HT3 antagonist are the preferred antiemetic regimens. For the prevention of acute emesis induced by low emetogenic chemotherapy a prophylaxis with a single antiemetic drug such as dexamethasone is suggested while no antiemetic prophylaxis should be administered to prevent acute emesis induced by minimal emetogenic chemotherapy or to prevent delayed emesis induced by low or minimal emetogenic chemotherapy. In this last case a rescue therapy should be administered in patients presenting acute or delayed emesis.

Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group.

1994 ◽  
Vol 12 (5) ◽  
pp. 1050-1057 ◽  
Author(s):  
L Kaizer ◽  
D Warr ◽  
P Hoskins ◽  
J Latreille ◽  
W Lofters ◽  
...  
Keyword(s):  
Emetogenic Chemotherapy ◽  
Phase Iii ◽  
Double Blind Study ◽  
Moderately Emetogenic Chemotherapy ◽  
Severe Nausea ◽  
Double Blind ◽  
Antiemetic Efficacy ◽  
Delayed Nausea ◽  
Nausea And Emesis ◽  
Oral Ondansetron

PURPOSE This study examines whether the schedule of ondansetron significantly influences its antiemetic efficacy in the first 24 hours after chemotherapy, whether the administration of oral ondansetron after 24 hours is effective in preventing delayed emesis, and whether the efficacy of ondansetron is preserved over multiple courses of moderately emetogenic chemotherapy. PATIENTS AND METHODS A multicenter double-blind study randomized 302 cancer patients to one of three treatment arms. Arm A received dexamethasone 10 mg intravenously (i.v.) plus ondansetron (Zofran; Glaxo Canada Inc, Toronto, Canada) 8 mg i.v. prechemotherapy plus ondansetron 8 mg orally every 12 hours postchemotherapy for nine doses. Arm B received dexamethasone 10 mg i.v. plus ondansetron 16 mg i.v. prechemotherapy plus placebo orally postchemotherapy in the same schedule as arm A. Arm C received dexamethasone 10 mg i.v. plus ondansetron 8 mg prechemotherapy plus ondansetron 8 mg orally postchemotherapy for one dose followed by placebo orally every 12 hours for eight more doses. Response was assessed by the number of reported episodes of vomiting and by severity of nausea measured on a visual analog scale (VAS). RESULTS The two schedules of ondansetron used in the first 24 hours were no different in their antiemetic efficacy, with similar rates for complete responses (76.7% v 72.0%, P = .472), complete plus major responses (90.2% v 82.0%, P = .135), and severity of nausea (P = .348). Oral ondansetron after 24 hours was more effective than placebo in preventing delayed nausea and emesis, with superior rates of complete responses (59.6% v 42.1%, P = .012 by one-sided test), complete plus major responses (80.9% v 66.3%, P = .018 by one-sided test), and less severe nausea (9.2 mm v 18.6 mm on a 100-mm VAS, P = .002). The efficacy of ondansetron was maintained over subsequent courses of chemotherapy. CONCLUSION The schedule of ondansetron in the first 24 hours does not influence its efficacy. The use of oral maintenance ondansetron is effective in preventing delayed maintenance ondansetron is effective in preventing delayed nausea and emesis after moderately emetogenic chemotherapy.

scholarly journals Effectiveness of antiemetics in control of antineoplastic chemotherapy-induced emesis at home

2014 ◽  
Vol 27 (5) ◽  
pp. 412-418 ◽  
Author(s):  
Marielly Cunha Castro ◽  
Suely Amorim de Araújo ◽  
Thaís Rezende Mendes ◽  
Glauciane Silva Vilarinho ◽  
Maria Angélica Oliveira Mendonça
Keyword(s):  
Breast Cancer ◽  
Emetogenic Chemotherapy ◽  
Nausea And Vomiting ◽  
Moderately Emetogenic Chemotherapy ◽  
Medical Prescription ◽  
Acute Emesis ◽  
Antineoplastic Chemotherapy ◽  
At Home

Objective Evaluating if antiemetics are effective in the prevention or treatment at home, of chemotherapy-induced emesis. Methods In total, were included 42 women with breast cancer in moderately emetogenic chemotherapy, using dexamethasone/ondansetron before each cycle. The frequency of nausea and vomiting was obtained by applying the instrument in the pre-chemotherapy period, and 24h, 48h, 72h and 96h after chemotherapy. The use of antiemetics was considered in accordance with adherence to medical prescription. Results All patients (n = 42, 100%) reported emesis at some point. Only five cases (11.9%) were anticipatory. In the first 24 hours (acute emesis), 38 (90.5%)ayed), emesis was reported by all despite the regular use (n = 20, 47.6%) or not (n = 22, 52.4%) of antiemetics (ondansetron, dexamethasone and metoclopramide/or dimenhydrinate). Conclusion Antiemetics were not effective in the prevention or treatment at home, of chemotherapy-induced emesis.

Sign in / Sign up

Export Citation Format

Share Document